cediranib

Overview

Cediranib is a pan-VEGFR (VEGFR1/2/3) small-molecule inhibitor also active against PDGFR and KIT. It has been investigated in clinical trials across multiple tumor types but is not FDA-approved as a standalone agent. In the UCLA sarcoma PDTO screen it showed differential sensitivity patterns related to treatment history and patient age.

Evidence in the corpus

  • In the UCLA sarcoma PDTO biobank (sarcoma_ucla_2024, n=194 specimens), sarcoma specimens with prior systemic therapy were more sensitive to cediranib than treatment-naïve specimens (p=0.017), alongside lenvatinib, cabozantinib, and everolimus. PMID:39305899
  • Pediatric and AYA sarcoma PDTOs were less resistant to cediranib than adult PDTOs (p=0.032 pediatric vs adult; p=0.013 AYA vs adult), suggesting age-related differences in tumor biology or VEGFR-pathway dependence. PMID:39305899
  • Leiomyosarcoma PDTOs were more sensitive to cediranib (along with dovitinib) compared to pan-sarcoma average (p=0.0068 for dovitinib; cediranib data pooled in the subtype sensitivity analysis). PMID:39305899

Resistance mechanisms

  • Not characterized in the sarcoma corpus.

Cancer types (linked)

  • LMS — leiomyosarcoma; sensitivity signals in PDTO screen.
  • OS, RMS — sarcoma subtypes in the pan-sarcoma screen panel.

Sources

  • PMID:39305899 — Al Shihabi et al. (Cell Stem Cell 2024). UCLA sarcoma PDTO biobank; cediranib prior-therapy enrichment and age-stratified sensitivity patterns.

This page was processed by crosslinker on 2026-05-04.